Lawrence C Long1, Mhairi Maskew, Alana T Brennan, Constance Mongwenyana, Cynthia Nyoni, Given Malete, Ian Sanne, Matthew P Fox, Sydney Rosen. 1. aDepartment of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand bHealth Economics and Epidemiology Research Office, Wits Health Consortium, Johannesburg, South Africa cDepartment of Global Health dDepartment of Epidemiology, School of Public Health, Boston University, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: Determine the cost and cost-effectiveness of single-visit (same-day) antiretroviral treatment (ART) initiation compared to standard of care initiation. DESIGN: Cost-effectiveness analysis of individually randomized (1 : 1) pragmatic trial of single-visit initiation, which increased viral suppression at 10 months by 26% [relative risk (95% confidence interval) 1.26 (1.05-1.50)]. SETTING:Primary health clinic in Johannesburg, South Africa. STUDY PARTICIPANTS: HIV positive, adult, nonpregnant patients not yet on ART or known to be eligible who presented at the clinic 8 May 2013 to 29 August 2014. INTERVENTION: Same-day ART initiation using point-of-care laboratory instruments and accelerated clinic procedures to allow treatment-eligible patients to receive antiretroviral medications at the same visit as testing HIV positive or having an eligible CD4 cell count. Comparison was to standard of care ART initiation, which typically required three to five additional clinic visits. MAIN OUTCOME MEASURE(S): Average cost per patient enrolled and per patient achieving the primary outcome of initiated 90 days or less and suppressed 10 months or less, and production cost per patient achieving primary outcome (all costs per primary outcome patients). RESULTS: The average cost per patient enrolled, per patient achieving the primary outcome, and production cost were $319, $487, and $738 in the standard arm and $451, $505, and $707 in the rapid arm. CONCLUSION: Same-day treatment initiation was more effective than standard initiation, more expensive per patient enrolled, and less expensive to produce a patient achieving the primary outcome. Omitting point-of-care laboratory tests at initiation and focusing on high-volume clinics have the potential to reduce costs substantially and should be evaluated in routine settings.
RCT Entities:
OBJECTIVE: Determine the cost and cost-effectiveness of single-visit (same-day) antiretroviral treatment (ART) initiation compared to standard of care initiation. DESIGN: Cost-effectiveness analysis of individually randomized (1 : 1) pragmatic trial of single-visit initiation, which increased viral suppression at 10 months by 26% [relative risk (95% confidence interval) 1.26 (1.05-1.50)]. SETTING: Primary health clinic in Johannesburg, South Africa. STUDY PARTICIPANTS: HIV positive, adult, nonpregnant patients not yet on ART or known to be eligible who presented at the clinic 8 May 2013 to 29 August 2014. INTERVENTION: Same-day ART initiation using point-of-care laboratory instruments and accelerated clinic procedures to allow treatment-eligible patients to receive antiretroviral medications at the same visit as testing HIV positive or having an eligible CD4 cell count. Comparison was to standard of care ART initiation, which typically required three to five additional clinic visits. MAIN OUTCOME MEASURE(S): Average cost per patient enrolled and per patient achieving the primary outcome of initiated 90 days or less and suppressed 10 months or less, and production cost per patient achieving primary outcome (all costs per primary outcome patients). RESULTS: The average cost per patient enrolled, per patient achieving the primary outcome, and production cost were $319, $487, and $738 in the standard arm and $451, $505, and $707 in the rapid arm. CONCLUSION: Same-day treatment initiation was more effective than standard initiation, more expensive per patient enrolled, and less expensive to produce a patient achieving the primary outcome. Omitting point-of-care laboratory tests at initiation and focusing on high-volume clinics have the potential to reduce costs substantially and should be evaluated in routine settings.
Authors: Alice A Zwerling; Maitreyi Sahu; Lucky G Ngwira; McEwen Khundi; Tina Harawa; Elizabeth L Corbett; Richard E Chaisson; David W Dowdy Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731
Authors: Kate Clouse; Audrey E Pettifor; Mhairi Maskew; Jean Bassett; Annelies Van Rie; Frieda Behets; Cynthia Gay; Ian Sanne; Matthew P Fox Journal: J Acquir Immune Defic Syndr Date: 2013-02-01 Impact factor: 3.731
Authors: Bruce Larson; Kathryn Schnippel; Buyiswa Ndibongo; Lawrence Long; Matthew P Fox; Sydney Rosen Journal: PLoS One Date: 2012-04-20 Impact factor: 3.240
Authors: Lawrence Long; Alana Brennan; Matthew P Fox; Buyiswa Ndibongo; Imogen Jaffray; Ian Sanne; Sydney Rosen Journal: PLoS Med Date: 2011-07-19 Impact factor: 11.069
Authors: Sydney Rosen; Mhairi Maskew; Matthew P Fox; Cynthia Nyoni; Constance Mongwenyana; Given Malete; Ian Sanne; Dorah Bokaba; Celeste Sauls; Julia Rohr; Lawrence Long Journal: PLoS Med Date: 2016-05-10 Impact factor: 11.069
Authors: Alberto Mateo-Urdiales; Samuel Johnson; Rhodine Smith; Jean B Nachega; Ingrid Eshun-Wilson Journal: Cochrane Database Syst Rev Date: 2019-06-17
Authors: Bruce A Larson; Sophie Js Pascoe; Amy Huber; Lawrence C Long; Joshua Murphy; Jacqui Miot; Matthew P Fox; Nicole Fraser-Hurt; Sydney Rosen Journal: J Int AIDS Soc Date: 2020-07 Impact factor: 5.396
Authors: Brooke E Nichols; Sarah J Girdwood; Thomas Crompton; Lynsey Stewart-Isherwood; Leigh Berrie; Dorman Chimhamhiwa; Crispin Moyo; John Kuehnle; Wendy Stevens; Sydney Rosen Journal: J Int AIDS Soc Date: 2019-09 Impact factor: 5.396
Authors: Sydney Rosen; Mhairi Maskew; Bruce A Larson; Alana T Brennan; Isaac Tsikhutsu; Matthew P Fox; Lungisile Vezi; Margaret Bii; Willem D F Venter Journal: PLoS Med Date: 2019-09-16 Impact factor: 11.069
Authors: Katleho Matsimela; Linda Alinafe Sande; Cyprian Mostert; Mohammed Majam; Jane Phiri; Vincent Zishiri; Celeste Madondo; Stephen Khama; Thato Chidarikire; Marc d'Elbée; Karin Hatzold; Cheryl Johnson; Fern Terris-Prestholt; Gesine Meyer-Rath Journal: BMJ Glob Health Date: 2021-07